- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | STOCKHOLM CORPORATE FINANCE: OncoZenge announces the final outcome of the rights issue | 2 | Cision News | ||
| Di | OncoZenge AB: OncoZenge announces the final outcome of the rights issue | 267 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 18.09. | OncoZenge AB: OncoZenge announces the preliminary outcome of the rights issue | 478 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 03.09. | Listing of subscription rights and paid subscription shares of OncoZenge AB | 271 | GlobeNewswire | With effect from September 04, 2026, the subscription rights in OncoZenge AB will be traded on First North Growth Market. Trading will continue up until and including September 15, 2026.
... ► Artikel lesen | |
| ONCOZENGE Aktie jetzt für 0€ handeln | |||||
| 31.08. | OncoZenge AB: OncoZenge AB advances global patent strategy for BupiZenge with filings in 17 markets | 347 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that it has entered the national and regional phase of its Patent Cooperation Treaty (PCT) application for BupiZenge in 17 jurisdictions.... ► Artikel lesen | |
| 31.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.08.2026 | 400 | Xetra Newsboard | Das Instrument 92Y NO0012477704 JACKTEL AS EQUITY wird cum Kapitalmassnahme gehandelt am 31.08.2026 und ex Kapitalmassnahme am 01.09.2026 The instrument 92Y NO0012477704 JACKTEL AS EQUITY is traded... ► Artikel lesen | |
| 28.08. | OncoZenge AB: Fourth tranche payment deadline expires without full payment from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd | 442 | GlobeNewswire (Europe) | Following the expiry of the payment deadline, OncoZenge AB (publ) ("OncoZenge" or the "Company") provides the following update on the status of the fourth tranche. The extended payment deadline for... ► Artikel lesen | |
| 28.08. | OncoZenge AB: OncoZenge secures bridge financing of SEK 2.0 million ahead of rights issue | 444 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company" or "OncoZenge") announces today, on 28 August 2026, that the Company has entered into a bridge loan agreement with John Haurum in the amount of SEK 2.0 million in... ► Artikel lesen | |
| 27.08. | OncoZenge AB: Investor withholds remaining payment for fourth tranche resulting in short-term liquidity shortfall | 198 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company") has received a letter from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd (the "Investor") with information that the Investor will withhold payment of... ► Artikel lesen | |
| 27.08. | OncoZenge AB: OncoZenge AB Interim Report January 1 - June 30, 2026 | 163 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the second quarter of 2026. The company reports receipt of regulatory approval to initiate patient recruitment... ► Artikel lesen | |
| 25.08. | OncoZenge AB: OncoZenge resolves on a rights issue of approximately SEK 33.3 million and publishes preliminary financial information for the second quarter of 2026 | 594 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 07.08. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds | 433 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1... ► Artikel lesen | |
| 17.07. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds | 356 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1... ► Artikel lesen | |
| 07.07. | OncoZenge AB: OncoZenge AB Announces Enrollment of First Patient in Pivotal Phase III BEAM-Pain Trial of BupiZenge | 1.120 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announces that the first patient has been... ► Artikel lesen | |
| 03.07. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Subscription Proceeds | 328 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the subscription proceeds of approximately SEK 15.1 million in... ► Artikel lesen | |
| 02.06. | OncoZenge AB: OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici | 234 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that the second milestone payment has been received from the Company's licensee, Molteni Farmaceutici.
The company announced on March... ► Artikel lesen | |
| 27.05. | OncoZenge AB: Bulletin From The Annual General Meeting Of OncoZenge | 232 | GlobeNewswire (Europe) | At the annual general meeting ("AGM") of OncoZenge AB (publ) held on 27 May 2026, the following principal resolutions were adopted, in accordance with the proposals submitted by the Board of Directors... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge | 786 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announced that it has received regulatory... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge AB Interim Report January 1 - March 31, 2026 | 259 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the first quarter of 2026. The company reports progress with European authorities expecting regulatory approval... ► Artikel lesen | |
| 22.05. | OncoZenge AB: OncoZenge enters into a loan agreement of SEK 2 million with Linc AB | 199 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") has today entered into an agreement regarding bridge financing of SEK 2 million through a loan provided by one of the Company's largest shareholders... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 33,890 | +0,62 % | Novo Nordisk, BioNxt Solutions, Evotec - wenn aus Spritzen Tabletten werden, klingelt die Kasse | Die tägliche Spritze hat ihre besten Tage hinter sich. Biologika als Tablette zu schlucken galt lange als Utopie, seit diesem Jahr wird daraus ein Milliardengeschäft. Am 17. September 2026 gab Novo... ► Artikel lesen | |
| ASTRAZENECA | 145,85 | -0,31 % | Zwischen Hoffnung und Risiko: Von der Forschung bis zur Diagnose: So verändert KI die Medizin | © Foto: wallstreetonline/KI - OpenAIKI soll Wirkstoffe schneller entwickeln, Diagnosen verbessern und Ärzte unterstützen. Doch eine Studie von Blue Cross zeigt auch die Risiken des Booms Enthaltene... ► Artikel lesen | |
| CAMURUS | 55,05 | +0,09 % | Camurus AB: Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA | PDUFA target action date set to 18 December 2026LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted... ► Artikel lesen | |
| BAYER | 50,02 | +1,30 % | Bayer bekommt plötzlich wieder Spielraum | Bei Bayer verschiebt sich die Geschichte schneller als das operative Geschäft. Über Jahre dominierte die Frage, wie teuer Monsanto am Ende noch werden könnte. 2026 hat sich diese Perspektive erstmals... ► Artikel lesen | |
| MERCK KGAA | 135,00 | +0,78 % | Bio-Techne Shareholders Approve Merck KGaA Acquisition Plan | WASHINGTON (dpa-AFX) - Wednesday, Bio-Techne Corp. (TECH) announced that its shareholders have approved the acquisition of the company by Merck KGaA (MKKGY.PK), Darmstadt, Germany, marking an... ► Artikel lesen | |
| JAGUAR HEALTH | 7,620 | -1,04 % | Morning Market Movers: Wheeler REIT, Professional Diversity Network, Jaguar Health, Greenland Mines See Big Swings | BEIJING (dpa-AFX) - At 6:50 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 57,68 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 21,520 | 0,00 % | Raymond James startet Coverage für Seaport Therapeutics mit "Strong Buy" - Potenzial bei Depressionsmedikament | ||
| SANOFI | 71,89 | +0,01 % | Sanofi: Was die Millionen-Steuerforderung jetzt bedeutet | ||
| SCHOTT PHARMA | 24,650 | +0,20 % | Schott Pharma: Was JPMorgans Kaufvotum jetzt auslöst | ||
| GENERATE BIOMEDICINES | 15,160 | 0,00 % | Generate Biomedicines auf dem Bernstein Healthcare Forum: Daten statt Modelle | ||
| PFIZER | 25,150 | -0,10 % | Pfizer vor Neubewertung? Warum die Gewinnschätzungen der Wall Street und der Aktienkurs auseinanderlaufen | Pfizer könnte vor einer Neubewertung stehen: Die aktuellen Konsensschätzungen der Analysten signalisieren eine deutliche Ergebnisdynamik, während der Aktienkurs diese Perspektive nach Einschätzung eines... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,675 | -0,11 % | Aquestive Therapeutics, Inc. - 8-K, Current Report | ||
| LB PHARMACEUTICALS | 37,330 | 0,00 % | LB Pharmaceuticals auf TD Cowen Summit: Wirkstoffkandidat LB-102 zielt auf sicherere psychiatrische Behandlungen ab | ||
| GILEAD SCIENCES | 131,18 | -0,94 % | Gilead Sciences und Assembly Bio: Kommt am 13. Oktober der Herpes-Paukenschlag? | Bei Gilead Sciences verdichten sich derzeit die Hinweise darauf, dass der Pharmakonzern in den kommenden Jahren das Therapiefeld der Virologie massiv ausbauen und damit die langfristige Abhängigkeit... ► Artikel lesen |
ONCOZENGE AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,286 Euro und damit -2,89 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOZENGE AB finden Sie auf Wallstreet Online.